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Abstract
Aims: Resistin is an adipocyte-derived factor implicated in obesity-associated type 2 diabetes
(T2DM). This study examines the association between human serum resistin, T2DM and coronary
heart disease.
Methods: One hundred and fourteen Saudi Arabian patients (male: female ratio 46:68; age 51.4
(mean ± SD)11.7 years; median and range: 45.59 (11.7) years and BMI: 27.1 (mean ± SD) 8.1 Kgm2
median and range: 30.3 (6.3) were studied. Serum resistin and C-reactive protein (CRP), a marker
of inflammation CRP levels, were measured in all subjects. (35 patients had type 2 diabetes mellitus
(T2DM); 22 patients had coronary heart disease (CHD).
Results: Serum resistin levels were 1.2-fold higher in type 2 diabetes and 1.3-fold higher in CHD
than in controls (p = 0.01). In addition, CRP was significantly increased in both T2DM and CHD
patients (p = 0.007 and p = 0.002 respectively). The use of regression analysis also determined that
serum resistin correlated with CRP levels (p = 0.04, R2 0.045).
Conclusion: The findings from this study further implicate resistin as a circulating protein
associated with T2DM and CHD. In addition this study also demonstrates an association between
resistin and CRP, a marker of inflammation in type 2 diabetic patients.
Introduction
Chronic sub-clinical inflammation has been identified as
an important mechanism in the pathogenesis of T2DM
and associated cardiovascular complications [1]. Obesity,
a major risk factor for T2DM and cardiovascular disease,
is now also established as a state of chronic inflammation
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important site for the production of pro-inflammatory
cytokines and acute phase reactants [3]. Such pro-inflam-
matory factors include tumour necrosis factor alpha (TNF-
α), interleukin 6 (IL-6) and leptin, which are secreted by
adipocytes [4-7] and are elevated in obesity and insulin
resistant states. This may therefore suggest the adipocyte
as a site also for an initial inflammatory response, there-
fore increasing the overlap between metabolic and
inflammatory signalling pathways.
The adipocytokine resistin which belongs to a family of
cysteine-rich C-terminal proteins known as resistin-like
molecules (RELM; RELMα/FIZZ 1 and RELMβ/FIZZ 2) of
FIZZ (found in inflammatory zone) are thought to be
involved in inflammatory processes [8-11]. Previous stud-
ies have however highlighted that in mice, resistin impairs
glucose tolerance and insulin action. In addition, resistin
also inhibits adipogenesis in murine 3T3-L1 cells [8,11-
14]. Therefore resistin has also been proposed as an adi-
pocyte-secreted factor thought to link obesity and T2DM
[9], although subsequent rodent studies have reported
contrasting findings to this [15]. In addition, the role of
resistin in human obesity has also produced conflicting
reports, and at present resistin still remains controversial
as a potential mediator in the pathogenesis of T2DM and
the impact of resistin on T2DM status [16-21].
Our previous studies have highlighted that serum resistin
levels are increased in Caucasian T2DM subjects and
reduced with modest weight loss [18,22] and these factors
are also associated with changes in C-reactive protein
(CRP) levels, CRP represents one of the acute phase pro-
teins which increase during systemic inflammation. CRP
is a known inflammatory marker for T2DM and coronary
heart disease (CHD) [23]. Our previous cohort studies
have also determined that with T2DM patients CRP repre-
sents an independent predictor of serum resistin levels
[18]. Furthermore, it is apparent that ethnicity can affect
the relative risk of T2DM and cardiovascular complica-
tions with South Asians, Arabs and Afro-Asians, with
T2DM having a higher adverse risk profile [24-29]. How-
ever, to date the relationship between serum resistin lev-
els, and T2DM or CHD has not been investigated in a
Saudi Arabian population. Therefore the aims of this
study were to investigate for the first time whether serum
resistin levels are increased in Saudi Arabians with T2DM
and if this is affected by CHD. Furthermore these studies
seek to ascertain whether CRP is correlated with serum
resistin levels in a Saudi Arabian population.
Materials and methods
Subjects
The type 2 diabetic patients for this study were randomly
selected from the Diabetes Center and non-diabetic case
control patients were obtained from out-patients of King
Abdulaziz University Hospital at King Saud University in
Riyadh, Saudi Arabia. Coronary heart disease (CHD)
patients were selected from the Coronary Care units at
King Khalid University Hospital and Prince Sultan Car-
diac Units in Riyadh. From these, 114 Saudi Arabian
patients were studied (Table 1). CHD patients (n = 22)
were classified as having coronary heart disease (CHD) if
they had suffered any of the following: a myocardial inf-
arction, angina with a positive exercise tolerance test, a
resting ECG consistent with CHD or angiographically
proven coronary artery disease. T2DM patients (n = 35),
diagnosed according to WHO criteria, but with no clinical
evidence of CHD were screened with ECG, clinical symp-
toms and ± thallium cardiac scanning or cathertization.
All patients with T2DM were treated by diet with or with-
out oral hypoglycemic agents, mainly glibenclamide and
metformin. Finally 50 Saudi individuals with no prior his-
tory of CHD or T2DM were recruited as healthy case con-
trols from general practice. Ethical approval was obtained
from the local institution's review committee.
Table 1: Clinical Characteristics of all patients
Case Control T2DM CHD
N 50 35 22
Age (years) 42.5(10.0) 53.6(11.7)a 47.6(11.9)
Diabetes duration (years) 0 6.8(6.3) 0
Systolic BP (mm/Hg) 117.7(16.7) 124.1(25.2) 135.0(20.7)
Diastolic BP (mm/Hg) 76.8(11.6) 78.8(14.5) 78.8(14.6)
BMI (KG/M2) 29.7(6.3) 27.5(6.9) 33.7(15.9)
Waist (cm) 94.1(15.0) 92.7(9.5) 91.4(12.2)
Hips (cm) 105.7(17.1) 95.0(15.6) 98.6(12.2)
Data are presented as mean ± (SD). Clinical characteristics for case control versus either type 2 diabetic or CHD patients were assessed (p-value: 
a = p < 0.01).Page 2 of 6
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completed a general questionnaire. Body mass index
(BMI), blood pressure, smoking habits and age were
recorded. Blood samples were collected after a 12-hr fast
for the determination of total cholesterol, HDL,
triglycerides, insulin, apolipoprotein AI (Apo AI) and
apolipoprotein AII (Apo AII), leptin and serum resistin
concentrations. These studies were conducted with the
approval of the King Abdulaziz Diabetic Center with
approval obtained from the ethics committee and the
individual consent of each patient.
Assays
Plasma samples were stored at -70°C prior to analysis.
Measurements of serum cholesterol, HDL, and triglycer-
ides, Apo AI and ApoAII were performed using routine
laboratory methods. Insulin was analysed by a solid phase
enzyme amplified sensitivity immunoassay (Medgenix
INS-ELISA, Biosource, Belgium). Insulin resistance
(HOMA IR) and β-cell function index were derived using
the HOMA equation [27]. Leptin concentrations were
measured by radio-immunoassay (Linco Research, St.
Charles, MO). CRP was analysed by immunoturbidimet-
ric method (Roche/ Hitachi analyser). Serum resistin was
measured using the human resistin ELISA assay from
Phoenix Pharmaceuticals (Belmont, California, USA;
intra-assay variability <5%). The commercially available
resistin ELISA had been validated as part of previous stud-
ies [15].
Statistical Analysis
Data were stored and analysed using the SPSS version 10
package (SPSS, Evanston, IL, USA) for Windows. Bio-
chemical parameters not normally distributed were ana-
lysed after being logarithmically transformed. A student's
unpaired t-test or one-way ANOVA exposed the differ-
ences between the groups. Simple and partial correlation
coefficients between the variables were determined and
multiple regression analysis was performed to determine
the relationships between the variables of interest. Data
were expressed as mean and standard deviation (SD) or
median and range; statistical significance was accepted at
p < 0.05.
Results
Clinical characteristics
The full clinical and biochemical characteristics for the
three groups are set out in Tables 1 and 2 respectively. The
control subjects were noted to be younger than the T2DM
patient counterparts (p < 0.01). However, there were no
significant differences in age or blood pressure, Body mass
index (BMI) or waist circumstance between case controls
and CHD patients.
Metabolic Characteristics
Serum resistin was significantly higher in T2DM 22.6(±
4.5)ng/mL and CHD patients 24.2(± 3.6) ng/mL com-
pared with case controls 18.9(± 3.4) ng/mL (p-value
<0.0001). CRP was significantly increased in T2DM 8.2
(0.7–27.1) µg/mL median (range) and CHD patients 7.3
(1.8–18.3) µg/mL(p = 0.007 and p = 0.002 respectively)
compared with case controls 4.9(0.2–18.9) µg/mL (Table
2). Regression analysis determined that serum resistin was
associated with serum CRP levels (Figure 1).
Fasting plasma glucose 15.4(5.4) serum cholesterol
15.4(5.4) mmol/L, LDL6.1(2.9) mmol/L and Apo-AI 70.8
(23.4)mg/dL were higher in T2DM patients (p < 0.0001,
Table 2: Metabolic Characteristics of all patients
Case Control T2DM CHD
N 50 35 22
Fasting Glucose mmol/L 5.4(1.4) 15.4(5.4)a 5.6(0.6)
Cholesterol mmol/L 5.3(1.3) 6.9(1.9)b 7.7(2.7)c
HDL mmol/L 0.9(0.4) 0.88(0.3) 0.92(0.4)
Triglyceride mmol/L 1.8(0.6) 2.5(1.1) 2.1(1.2)
LDL mmol/L 3.9(1.4) 6.1(2.9)d 4.9(1.9)e
Insulin (Range) µmol/L* 7.5(5–12) 9.0(9–16) 7.0(1–49)
Leptin (Range)ng/mL* 7.2(2–30) 5.8(1.9–28) 3.7(0.7–8.9)
Apo1 mg/dL 80.1(15.6) 70.8.(23.4)c 74.1(24.5)
Apo11 mg/dL 48.7(13.5) 45.9(13.6)f 46.3(18.9)c
HOMAIR (Range)* 1.8(1.3–3.2) 8.2(0.8–49.7) 2.0(0.5–5.6)
Resistin ng/mL 18.9(3.4) 22.6(4.5)e 24.2(3.2)d
CRP (Range) µg/mL* 4.9(0.2–18.9) 8.2(0.7–27.1)g 7.3(1.8–18.3)f
Data are presented as means (SD) or as median (interquartile range) for insulin, leptin HOMIR and CRP data. P-values shown are comparison of 
metabolic characteristics for case control versus either type 2 diabetic (T2DM) or coronary heart disease (CHD) patients as highlighted: a = p < 
0.0001, b = p < 0.05, c = p < 0.003, d = p < 0.017, e = p < 0.01, f = p < 0.002, g = p < 0.007.Page 3 of 6
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with case control subjects, while the Apo-AII 45.9
(13.6)mg/dL was lower in the T2DM than in the controls,
where p < 0.002 (Table 2). In CHD, cholesterol 7.7 (2.7),
and LDL 4.9(1.9) mmol/L were significantly higher than
in the case controls (p = 0.003, p < 0.01 respectively; while
the Apo-AII 46.3(18.9) mg/dL in CHD patients as lower
than in the case controls, where p = 0.003 (Table 2).
Univariate analysis
Univariate analysis for all groups showed strong positive
associations between resistin and fasting glucose (p =
0.01, Figure 2), and negative association with hip circum-
ference (R2 0.6, p = 0.004, p = 0.03 respectively) but in
CHD patients, resistin had a strong positive association
with systolic and diastolic blood pressure and Apo-AII (R2
0.82, p < 0.0017, R2 = 0.45 p < 0.002 respectively). There
was also a strong correlation with Apo-AII (p < 0.003),
whereas, in T2DM patients, resistin was correlated with
LDL (R2 = 0.79, p = 0.009).
Discussion
While it is apparent there are conflicting reports as to the
role of serum resistin and its role in obesity mediated
T2DM, no study to date has examined this in relation to a
Saudi population with and without T2DM and/or CHD.
This study determined that serum resistin levels were
increased in T2DM and CHD in a Saudi population, when
compared with case control subjects.
In addition it was demonstrated that a correlation exists
between serum resistin and CRP levels in Saudi subjects,
confirming our studies in Caucasian non-diabetic and
T2DM subjects [18]. These data further suggest a potential
role for resistin as a marker associated with inflammation
in both T2DM and CHD disease. Studies have already
shown pro-inflammatory cytokines to be important
inducers of CRP, such as IL-6, TNF-α, and leptin [31], and
resistin may also play a role as an inducer of CRP.
Other studies have examined the relationship between
BMI and serum resistin levels. However, while some stud-
ies have shown such results as correlation [16], this study
and our previous study [18] failed to determine such an
effect. The relationship of resistin with increasing adipos-
ity was not a primary determinant of this study and as
such the range of BMI across this cohort may not be suffi-
cient to identify a correlation. However, a negative corre-
lation of serum resistin with hip circumference was noted,
supporting a possible link between resistin and obesity.
Our earlier and present studies also investigated whether
there was any correlation between serum resistin levels
and fasted glucose levels across all the subjects. A
significant correlation between fasting glucose and serum
resistin was observed. This supports the previous finding
by Lazar and his co-workers from their rodent model stud-
ies, where fasted blood glucose was higher in resistin-
The correlation of Serum resistin levels (ng/mL) with C-reac-tiv  prot in (mg/mL) using univariate analysis across all Saudi subjects, case controls, T2DM d CHD subje tsFigure 1
The correlation of Serum resistin levels (ng/mL) with C-reac-
tive protein (mg/mL) using univariate analysis across all Saudi 
subjects, case controls, T2DM and CHD subjects. Black 
denotes the actual values with the line of best fit shown in 
square (R2 0.045 p-value = 0.04).
The correlation of Serum resistin levels (ng/mL) with glucose (mmol/L) acr ss Saudi subject  with univariate analysis acr sall case con r l , T2DM and CHD s bjectsFigur  2
The correlation of Serum resistin levels (ng/mL) with glucose 
(mmol/L) across Saudi subjects with univariate analysis across 
all case controls, T2DM and CHD subjects. Blue denotes the 
actual values with the line of best fit shown in pink (R2 = 0.03, 
p-value = 0.01).
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and glucose tolerance was impaired in the hyper-resistine-
mic mice [32].
However in vivo human analysis of the relationship
between serum resistin and glucose has produced
conflicting reports [17,18,33,34]. No correlations were
identified in serum resistin and glucose amongst non-
obese, obese and obese T2DM subjects by examining the
glucose disposal rate during a hyperinsulinaemic glucose
clamp across groups [17]. In conjunction with this, an in
vivo analysis by Azuma et al. also noted no significant cor-
relation in serum resistin and glucose with cross-sectional
analysis; but longitudinal analysis in the same cohort
revealed changes in serum resistin to be positively corre-
lated with glucose as well as other factors such as BMI, and
insulin [34]. Hence, these studies may suggest that cross
sectional analysis of serum resistin may also be inade-
quate to determine correlations. Further, the specificity of
the resistin ELISA assay emerges as an important factor in
these and other studies; to date, however, only one com-
mercial ELISA appears to have been validated for cross-
reactivity with different members of the RELM family and
this may affect the findings in other studies [18].
Additional in vitro studies in human adipose cells sup-
ports the role of resistin in reducing glucose uptake, with
the effect of revealing a potential functional role for resis-
tin in in vivo metabolism [18].
In conclusion, these present findings suggest that resistin
may have a dual role involved in sub-clinical inflamma-
tion as well as in altering glucose metabolism leading to
the progression of T2DM in this Saudi cohort. As such,
this study may add to the current speculation over the
roles and actions of resistin, since studies continue to
suggest a role for resistin in affecting glucose, insulin sen-
sitivity and sub-clinical inflammation.
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